Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Konin – page 2

45 clinical trials in Konin, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Konin at a glance
45
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

45 trials in Konin

Open in trial search

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Macrogenics Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Macrogenics Inc.

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan and Drug Combination for Patients with HER2-Positive Gastric, GEJ, and Esophageal Cancer

Not recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of head and neck

Not recruiting

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Inhibrx Biosciences Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Konin

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials exploring treatments for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), including studies of novel immunotherapy combinations and targeted therapies.

  • Advanced/metastatic NSCLC treatments
  • Extensive-stage SCLC therapies
  • Immunotherapy combinations

Multiple studies evaluating new drug combinations to improve survival rates and treatment outcomes.

02 Breast Cancer Innovations

Research focusing on hormone receptor-positive, HER2-negative breast cancer, investigating novel therapeutic approaches and combination treatments.

  • Advanced/metastatic breast cancer
  • Targeted therapy combinations
  • Hormone therapy resistance

Studies examining new treatment options for patients with advanced breast cancer, particularly those who have progressed after prior therapies.

03 Gastrointestinal Oncology

Clinical trials investigating treatments for colorectal cancer and gastric cancer, including studies of targeted therapies and immunotherapy approaches.

  • HER2-expressing gastric cancer
  • BRAF-mutant colorectal cancer
  • Combination therapy approaches

Research focused on improving treatment outcomes through targeted therapeutic strategies and novel drug combinations.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.